Azorín-Vega Erika, Rojas-Calderón Eva, Ferro-Flores Guillermina, Aranda-Lara Liliana, Jiménez-Mancilla Nallely, Nava-Cabrera Miguel A
Departamento de Materiales Radiactivos, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac, 52750, Estado de México, Mexico.
Departamento de Ciencias Ambientales, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac, 52750, Estado de México, Mexico.
Appl Radiat Isot. 2019 Apr;146:66-71. doi: 10.1016/j.apradiso.2019.01.020. Epub 2019 Jan 29.
This research aimed to assess the radiation absorbed dose produced by Lu-iPSMA (Lu-prostate specific membrane antigen inhibitor), Ac-iPSMA and RaCl to prostate cancer cell nuclei in a simplified model of bone by using an experimental in-vitro prostate cancer LNCaP cell biokinetic study and Monte Carlo simulation with the MCNPX code. Results showed that Ac-iPSMA releases a nine hundred-fold radiation dose greater than Lu-iPSMA and 14 times more than RaCl per unit of activity retained in bone. Ac-iPSMA could be the best option for treatment of bone metastases in prostate cancer.
本研究旨在通过体外前列腺癌LNCaP细胞生物动力学实验研究以及使用MCNPX代码进行蒙特卡罗模拟，在简化的骨模型中评估镥-前列腺特异性膜抗原抑制剂（Lu-iPSMA）、锕-前列腺特异性膜抗原（Ac-iPSMA）和氯化镭（RaCl）对前列腺癌细胞核产生的辐射吸收剂量。结果表明，每单位保留在骨中的活度，Ac-iPSMA释放的辐射剂量比Lu-iPSMA高900倍，比RaCl高14倍。Ac-iPSMA可能是治疗前列腺癌骨转移的最佳选择。
